Key Research Initiatives

Key Research Initiatives

Hudson Heights is currently requesting proposals to develop innovative therapeutic strategies to treat rare genetic diseases.

All rare diseases with a known genetic cause that can be diagnosed with the aid of clinical sequencing are eligible. Preference is given to diseases with existing patient communities and clear clinical measures.

Disorders or conditions with a prevalence of fewer than 200,000 people in the U.S. are considered rare diseases. All rare diseases with a known genetic cause that can be diagnosed with the aid of clinical sequencing are eligible. Preference is given to diseases with existing patient communities and clear clinical measures.

Each therapeutic discovery project supported by this funding opportunity must focus on a clear therapeutic hypothesis enabled by genetic and biological understanding of disease pathophysiology with cellular and in vivo models available. Existing therapeutic candidates are not required.

Therapeutics of interest include small molecules, biopharmaceuticals, and gene therapies.

Interested faculty should email Samantha Galindo (s.galindo@columbia.edu) for next steps and formal submission.